✦ Pfizer Inc. unveiled its launch strategy for three biosimilars. Zirabev (bevacizumab-bvzr) launched Dec. 31 at a wholesale acquisition cost (WAC) of $61.343 per 10 mg, a 23% discount to that of reference drug Avastin (bevacizumab), from Genentech USA, Inc., a member of the Roche Group. Ruxience (rituximab-pvvr) launched Jan. 23 at a WAC of $71.68 per 10 mg, a 24% discount to the WAC of reference drug Rituxan (rituximab) from Genentech and Biogen. And Trazimera (trastuzumab-qyyp) will launch Feb. 15 with a WAC of $80.74 per 10 mg, a 22% discount to that of Genentech’s Herceptin (trastuzumab). View the press release at https://bit.ly/2RV1vll.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.